Novel treatment of antibioticresistant Gram-positive infections

Important results from the project

** Denna text är maskinöversatt ** The overall objective of the project is to develop new small molecules for the treatment of antibiotic-resistant infections caused by Gram-positive bacteria. These so-called GmPcides have the ability to enhance the effect of existing antibiotics and our vision is that the substances should be used to treat healthcare-associated infections where antibiotic resistance is a growing problem that threatens all modern healthcare and we have now taken several important steps to approach this objective.

Expected long term effects

** Denna text är maskinöversatt ** We have developed a TPP and a regulatory plan for the treatment of complicated urinary tract infection, which has been identified as the most suitable indication for the first human studies. Together with formulation experts, we have developed a preformulation suitable for intravenous or subcutaneous administration, which makes it possible to start treatment studies in animal models with a clinically relevant route of administration. The project has provided knowledge that will allow the preclinical development to begin more quickly.

Approach and implementation

** Denna text är maskinöversatt ** The project´s layout with four separate work packages has worked well and the cooperation between the parties in the project has been managed via regular meetings. The implementation of the project has been affected to some extent by the Corona pandemic, partly because staff have been absent due to quarantine or illness and partly because of delayed material deliveries. Despite delays, the project has completed the planned activities in the four work packages.